Renger T.
- Country
- The Netherlands
- Department
- Program Management
Research Overview
- Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INE963 in Patients with Malaria
- Phase 1 Study on Mass Balance, Pharmacokinetics, and Metabolism of Oral [14C]-Zipalertinib in Healthy Adult Male Subjects with Cancer
- Pharmacokinetic Study of [14C]DLX313 (Minzasolmin) in Healthy Male Subjects with Parkinson’s Disease
Data & Insights
Has run more than one trial at 1 of 2 partner sites.
Specializations
Neurological Research
The investigator specializes in studies related to neurodegenerative disorders, with particular emphasis on movement disorders and mental health conditions.
- Parkinson's Disease therapeutics
- Major Depressive Disorder treatment approaches
Their work includes evaluation of novel therapeutic compounds for neurological conditions.
Oncology Studies
The investigator conducts research in cancer therapeutics, focusing on targeted treatments for specific mutations.
- Non-small cell lung cancer with genetic mutations
- EGFR and HER2 mutation targeted therapies
Their research includes investigation of novel compounds for cancer treatment.
Other Therapeutic Areas
The investigator's expertise extends to various other medical conditions and therapeutic approaches.
- Inflammatory disease treatments
- Primary sclerosing cholangitis research
- Anti-malarial drug development
Their work encompasses both rare diseases and widespread health conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.